A previous study showed that fusing LLO protein to human papillomavirus E7 protein improved the tumoricidal function of E7-specific CD8+ T cells and increased the number of antigen-specific CD8+ T cells in the tumor (Lamikanra et al., 2001), resulting in an improved antitumor therapeutic effect. The gene discussed is CD8A; the disease is neoplasm.